SILTRAX EPI NO. 10
Natural health product licensed in Canada
- Licence holder
- Pascal International Corporation
- NPN or DIN-HM
- 02097729
- Status
- Active licence
- Licence date
- 10 October 2007
- Revision date
- Not provided
- Form
- Ficelle
- Route of administration
- Buccale, Dentaire
- Application type
- DIN de transition
Oral dose analysis does not apply without an established exclusively oral route.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Eau purifiée, Phosphate de sodium, monobasique, Cotton Cord Twisted # 9, éthanol anhydre, Hydroxyde d'ammonium, Chlorure de zinc, alcool benzylique, Sodium Dithionite, Chlorure de sodium, Sodium Bisulfite, Sodium Thiosulphate, anhydrous, Acide phosphorique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants | Not specified | minimum: 1 cord | Not specified |
| Adultes | Not specified | minimum: 1 cord | Not specified |
Uses authorised in Canada
Use whenever gingival retraction is advisable in dental practice; as preceding impression taking with any elastic impression material; or prior to placement of caps, crowns, bridges, etc. SIL-TRAX EPI is braided cotton cord saturated with a solution of Racemic epinephrine hydrochloride dried by a technique which retains the activity of the medication. Normal tissue moisture reactivates the medication, which promptly retracts gingival tissue in a manner that causes no tissue damage, yet fully exposes the gingival margin.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Retraction with an epinephrine cord should be limited to the equivalent of one normal quadrant of the mouth per appointment.
- Contre-indications
SIL-TRAX EPI is contraindicated for persons who are epinephrine sensitive, or for persons suffering from cardiovascualr disease, diabetes, or hyperthyroidism.
- Effets indésirables connus
Contains Sodium Bisulfate, a sulfite that may cause allergic types of reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
Source
Official Health Canada record, licence 02097729
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.